NORADRENALINA E DEPRESSIONE

Ruolo del sistema noradrenergico nella fisiopatologia della depressione e nel meccanismo d'azione degli antidepressivi

Nicoletta Brunello¹ e Joan M.C. Blom^1,2

• TEORIA AMINERGICA DELLA DEPRESSIONE
• RUOLO DELLA NORADRENALINA NELLA DEPRESSIONE
• INIBITORI SELETTIVI DEL REUPTAKE DELLA NORADRENALINA
• BIBLIOGRAFIA

Brunello N., Racagni G. (1998) Rationale for the development of noradrenaline reuptake inhibitors. Human Psychopharmacology, 13: S13-S19.

Delgado PL., Miller HL., Salomon RM., Licinio J., et al., (1993) Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacology Bulletin, 29: 389-396.

Delgado PL., Moreno FA., Potter R., Gelenberg AJ. (1997) Norepinephrine and serotonin in antidepressant action: evidence from neurotransmitter depletion studies. In Briley M. (ed), Antidepressant Therapy at the Dawn of the Third Millennium. London: Martin Dunitz Ltd; pp 141-163.

Dostert P., Strolin-Benedetti S., Poggesi I. (1997) Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur. Neuropsychopharmacology, 7: 23-35.

Dubini A., Bosc M., Polin V. (1997) Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effect on social functioning. J Psychopharmacol 11: S17-S23.

Extein J., Tallman J., Smith CC:, Goodwin FK. (1979) Changes in lymphocyte beta-adrenergic receptors in depression and mania. Psychiatry Research 1: 191-197.

Karege F., Bovier P., Gaillard JM., Tissot R. (1989) The heterogeneity of 3-metoxy-4-hydroxyphenylglycol levels among depressed patients. Acta Psych. Scandinavica 80: 499-504.

Leonard BE. (1986) Neurotransmitter receptors, endocrine responses and the biological substrates of depression: a review. Human Psychopharmacology. 1: 3-18.

Leonard BE. (1997) The role of noradrenaline in depression: a review. J Psychopharmacol 11: 39-47.

Melloni P., Carniel G., Della Torre A., et al., (1984) Potential antidepressant agents. Alpha-aryloxy-benxyl derivatives of ethanolamine and morpholine. Eur. J. Med. Chemistry 19: 235-242.

Miller HL., Delgado PL., Salomon RM. et al., (1996) Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch. Gen. Psychiatry 53:, 117-128

Montgomery SA. (1997) Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 11: 9-15.

Mucci M. (1997) Reboxetine: a review of antidepressant tolerability. J Psychopharmacol 11: 33-37.

Nutt DJ. (1997) Noradrenaline in depression: Half a century of progress. Journal of Psychopharmacology 11: S3.

Ordway GA, Stockmeier CA, Cason GW, Klimek V. (1997) Pharmacology and distribution of norepinephrine transporters in the human locus coeruleus and Raphe nuclei. J Neurosci; 17: 1710-1719.

Riva M., Brunello N., Rovescalli AC., Galimberti R., Carfagna N., Carminati P., Pozzi O., Ricciardi S., Roncucci R., Rossi A., Racagni G. (1989) Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: behavioural and biochemical studies. J Drug Development 1: 243-253.

Schatzberg AF, Schildkraut JJ. (1995) Recent studies on norepinephrine systems in mood disorders. In Psychopharmacology: the Fourth Generation of Progress. Bloom FE. and Kupfer DJ. (eds) Raven Press, New York, pp. 911-920.

Schildkraut JJ, (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiat. 122:509-522.

Siever LJ., Uhde TW., Jimerson DC. et al. (1983) Clinical studies of monoamine receptors in the affective disorders and receptor changes with antidepressant treatment. Prog Neuro-Psychopharmacol Biol Psychiatr, 7: 249-261.

 

1Dipartimento di Scienze Farmaceutiche, Università degli Studi di Modena e Reggio Emilia

2 I.R.C.C.S. San Giovanni di Dio-Fatebenefratelli, Brescia